<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04750408</url>
  </required_header>
  <id_info>
    <org_study_id>01</org_study_id>
    <nct_id>NCT04750408</nct_id>
  </id_info>
  <brief_title>NHF vs. COT in Hypoxemic Pandemic Viral Illness</brief_title>
  <acronym>HIVI</acronym>
  <official_title>Clinical Effects of Nasal High-flow Compared to Oxygen in Acute Viral Illness</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Jens Bräunlich</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Klinikum Emden</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The study compares oxygen and NHF in patients with acute viral illness. The duration will be&#xD;
      72h. After them physiological parameters and the outcome will be evaluated.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">January 22, 2021</start_date>
  <completion_date type="Anticipated">April 22, 2021</completion_date>
  <primary_completion_date type="Anticipated">March 22, 2021</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Rox index</measure>
    <time_frame>72 hours</time_frame>
    <description>(SpO2/FiO2)/RR = index without a unit, mean Rox-index in the two groups, comparison between the groups (significant differences), physiological parameter, to assess differences between the two groups</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>paCO2 in mmHg</measure>
    <time_frame>72 hours</time_frame>
    <description>physiological parameter, to assess differences between the two groups</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>pH</measure>
    <time_frame>72 hours</time_frame>
    <description>physiological parameter, to assess differences between the two groups</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>escalation of therapy</measure>
    <time_frame>72 hours</time_frame>
    <description>use of noninvasive ventilation, intubation, to assess differences between the two groups</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>paO2 in mmHg</measure>
    <time_frame>72 hours</time_frame>
    <description>physiological parameter, to assess differences between the two groups</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">52</enrollment>
  <condition>Acute Viral Bronchitis</condition>
  <condition>Hypoxemic Respiratory Failure</condition>
  <condition>Hypercapnic Respiratory Failure</condition>
  <arm_group>
    <arm_group_label>Oxygen use</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Patients will use standard oxygen via face mask of nasal prongs as usual care.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>NHF use</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Patients will use NHF instead of oxygen. Oxygen will be supplemented via the NHF flow.</description>
  </arm_group>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>Standard oxygen</intervention_name>
    <description>COT describes the application of low-flow oxygen in any way (Hudson mask, nasal prongs,...).</description>
    <arm_group_label>Oxygen use</arm_group_label>
    <other_name>COT</other_name>
  </intervention>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>Nasal high-flow</intervention_name>
    <description>F is combination of room air supplemented with oxygen can be better patients. This gas mixture will be provided to the patient with a specialized nasal prong.</description>
    <arm_group_label>NHF use</arm_group_label>
    <other_name>NHF</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  acute hyperemic viral illness&#xD;
&#xD;
          -  acute hyperemic or hypercapnia respiratory failure&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  intubation criteria&#xD;
&#xD;
          -  indication for NIV therapy&#xD;
&#xD;
          -  influences of primary endpoint (rip fracture, lung embolism)&#xD;
&#xD;
          -  tracheostomy&#xD;
&#xD;
          -  other interventional trials&#xD;
&#xD;
          -  noncompliance&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>100 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Jens Bräunlich, MD</last_name>
    <role>Study Chair</role>
    <affiliation>chair</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Jens Bräunlich, MD</last_name>
    <phone>+494921981598</phone>
    <email>highflow@web.de</email>
  </overall_contact>
  <location>
    <facility>
      <name>Klinikum Emden</name>
      <address>
        <city>Emden</city>
        <zip>26721</zip>
        <country>Germany</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Jens Bräunlich, MD</last_name>
      <phone>+494921981598</phone>
      <email>highflow@web.de</email>
    </contact>
  </location>
  <location_countries>
    <country>Germany</country>
  </location_countries>
  <verification_date>February 2021</verification_date>
  <study_first_submitted>January 21, 2021</study_first_submitted>
  <study_first_submitted_qc>February 7, 2021</study_first_submitted_qc>
  <study_first_posted type="Actual">February 11, 2021</study_first_posted>
  <last_update_submitted>February 22, 2021</last_update_submitted>
  <last_update_submitted_qc>February 22, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">February 24, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor-Investigator</responsible_party_type>
    <investigator_affiliation>Klinikum Emden</investigator_affiliation>
    <investigator_full_name>Jens Bräunlich</investigator_full_name>
    <investigator_title>Chair Pneumology and Respiratory Medicine</investigator_title>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Bronchitis</mesh_term>
    <mesh_term>Respiratory Insufficiency</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>Yes</sharing_ipd>
    <ipd_description>original/ raw data</ipd_description>
    <ipd_info_type>Study Protocol</ipd_info_type>
    <ipd_info_type>Informed Consent Form (ICF)</ipd_info_type>
    <ipd_time_frame>after the end of the study</ipd_time_frame>
    <ipd_access_criteria>on request</ipd_access_criteria>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

